$Lucid Diagnostics (LUCD.US)$ NEWS Lucid Diagnostics Announc...
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89% sensitivity showcases the effectiveness and accuracy of the Esophageal DNA Test.
The study's results further support ongoing engagement to secure commercial and Medicare payor coverage, indicating a potential increase in market adoption and revenue for Lucid Diagnostics.
The high sensitivity and estimated negative predictive value of EsoGuard represent significant advancements in early detection technology for esophageal cancer, potentially saving lives through early intervention.
EsoGuard's demonstration of unprecedented early precancer detection with 89% sensitivity showcases the effectiveness and accuracy of the Esophageal DNA Test.
The study's results further support ongoing engagement to secure commercial and Medicare payor coverage, indicating a potential increase in market adoption and revenue for Lucid Diagnostics.
The high sensitivity and estimated negative predictive value of EsoGuard represent significant advancements in early detection technology for esophageal cancer, potentially saving lives through early intervention.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1103Followers
69Following
7648Visitors
Follow